BioSpace News Archive

Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that it will present an overview of its business and clinical programs at the Sidoti Micro-Cap Virtual Conference, taking place January 17-18, 2024.

AIM ImmunoTech Inc. today announced that enrollment is open at Erasmus Medical Center (“Erasmus MC”) in a Phase 1b/2 clinical trial combining AIM’s Ampligen ® (rintatolimod) with AstraZeneca’s anti-PD-L1.

U.S. Orthopaedic Partners, a prominent, multi-state orthopaedic care platform, proudly announces the appointment of Stephen G. Holtzclaw, MD, MBA, as its new chief executive officer, effective January 1, 2024.

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by UCB to dispense ZILBRYSQ®, a new FDA-approved therapy for the treatment of adults with gMG who are anti-AChR antibody positive.

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) announces that Dr. Michael Gross has retired from the Company’s Board of Directors (the “Board”) to focus on other business interests.

Medicinal chemists at Usona Institute have designed a series of new compounds inspired by norpsilocin, a tryptamine natural product found in psychedelic mushrooms.

According to preclinical research published online in Cell researchers with City of Hope®, one of the largest cancer treatment and research organizations in the United States, have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer.

Lykos Therapeutics (formerly MAPS Public Benefit Corporation) (“Lykos”) announced that PLOS ONE has published the first comparison of the effects of investigational MDMA-assisted therapy and therapy with placebo on emotional coping skills and self-experience in adults with severe post-traumatic stress disorder (“PTSD”).

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”) today announced it has entered into an exclusive multi-year distribution agreement with Stedical Scientific, Inc. to commercialize PermeaDerm® Biosynthetic Wound Matrix in the United States.

Integer Holdings Corporation announced fourth quarter 2023 preliminary unaudited sales are expected to be in the range of $411 million to $413 million, an increase of 10% to 11% compared to fourth quarter 2022.